{"id":78554,"date":"2026-09-03T17:55:03","date_gmt":"2026-09-03T09:55:03","guid":{"rendered":"https:\/\/flcube.com\/?p=78554"},"modified":"2026-09-03T17:55:04","modified_gmt":"2026-09-03T09:55:04","slug":"neushen-therapeutics-closes-oversubscribed-series-b-exceeding-usd-80-million-to-accelerate-global-cns-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78554","title":{"rendered":"NeuShen Therapeutics Closes Oversubscribed Series B Exceeding USD 80 Million to Accelerate Global CNS Pipeline"},"content":{"rendered":"\n

NeuShen Therapeutics<\/strong> announced the successful closing of an oversubscribed Series B<\/strong> financing round exceeding USD 80 million, reinforcing investor confidence in its differentiated CNS<\/strong> pipeline. Led by a leading industrial capital investor with participation from B Capital, Legend Capital, Matrix Partners China, Zhenmai Capital, and SDIC Venture Capital \u2014 plus continued follow\u2011on investment from existing shareholder Lilly Asia Ventures (LAV) \u2014 the round ranks among the larger recent private financings dedicated to central nervous system drug discovery.<\/p>\n\n\n\n

Financing Terms at a Glance<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/td>NeuShen Therapeutics<\/strong><\/td><\/tr>
Round<\/td>Series B<\/strong>, oversubscribed<\/td><\/tr>
Size<\/td>Exceeding USD 80 million<\/td><\/tr>
Lead Investor<\/td>Leading industrial capital investor<\/td><\/tr>
Participating Institutions<\/td>B Capital, Legend Capital, Matrix Partners China, Zhenmai Capital, SDIC Venture Capital<\/td><\/tr>
Existing Shareholder<\/td>Lilly Asia Ventures (LAV) added to its investment<\/td><\/tr>
Use of Proceeds<\/td>Expand CNS<\/strong> innovative pipeline; accelerate global clinical development of core programs; explore breakthrough therapies for major unmet medical needs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pipeline Snapshot \u2013 Three Core Clinical Programs<\/h2>\n\n\n\n
Program<\/th>Mechanism<\/th>Indication<\/th>Stage<\/th><\/tr><\/thead>
NS\u2011079<\/td>Non\u2011hallucinogenic 5\u2011HT2A receptor partial agonist<\/td>Depressive disorders<\/td>First\u2011in\u2011human trial initiated in Australia<\/td><\/tr>
NS\u2011136 (laviclidine)<\/td>Novel highly selective M4 receptor positive allosteric modulator<\/td>Acute\u2011phase schizophrenia<\/td>Phase II in China<\/td><\/tr>
NS\u2011136 (laviclidine)<\/td>Same mechanism<\/td>Agitation symptoms associated with Alzheimer’s disease<\/td>Phase II approved by NMPA<\/strong> and U.S. FDA<\/strong><\/td><\/tr>
NS\u2011041 (zolankalner)<\/td>Highly selective KCNQ2\/3 channel agonist<\/td>Focal\u2011onset seizures<\/td>Phase II multicenter trial, patient enrollment underway<\/td><\/tr>
NS\u2011041 (zolankalner)<\/td>Same mechanism<\/td>Major depressive disorder<\/td>Phase II actively being prepared<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

All three core programs are in clinical development, with mechanisms spanning serotonergic, cholinergic, and ion\u2011channel targets \u2014 a breadth that gives NeuShen<\/strong> multiple independent shots at breakthrough CNS<\/strong> therapies.<\/p>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n